The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies
Torben Plesner
• 4 May 2018
The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the variety of agents used in the therapeutic management of MM. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.
